Drug Trial Radar · NCT07467707
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6,144
Planned (sponsor's estimate)
Start
May 26, 2026
Primary completion
May 2030
Study completion May 2030
Sponsor
- Lead sponsor
- Bavarian NordicIndustry
- Sponsor type
- Industry
- Collaborators
- Walter Reed Army Institute of Research (WRAIR); Congressionally Directed Medical Research Programs; United States Department of Defense; Pharmaceutical Product Development, (PPD) LLC; Armed Forces Research Institute of Medical Services; Q-square Business Intelligence, Inc.
- First posted
- Mar 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities, and optimize the study parameters to local epidemiological conditions for CHIKV disease to overcome the challenges of assessing efficacy for CHIKV VLP vaccine.
Conditions
- Chikungunya Virus
Interventions
CHIKV VLP vaccineBiological
CHIKV VLP vaccine is comprised of 40 µg CHIKV VLP adsorbed on aluminum hydroxide (corresponding to approximately 300 µg of aluminum and stabilized with formulation buffer). CHIKV VLP vaccine is supplied as a single dose of 0.8 mL in a single use pre-filled syringe administered via IM injection in the deltoid muscle.
PlaceboBiological
Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a single use pre-filled syringe administered via IM injection in the deltoid muscle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of laboratory-confirmed acute CHIKV diseaseTime frame: From 14 days postvaccination through end of study follow-up, up to 1095 days postvaccination
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
WRAIR-AFRIMS Philippines, Cebu (WRAIR-APC)
Cebu City, Cebu, Philippines · Recruiting
Kamphaeng Phet Provincial Hospital
Kamphaeng Phet, Changwat Kamphaeng Phet, Thailand · Recruiting
Songklanagarind hospital, Prince of Songkla University (PSU)
Hat Yai, Changwat Songkhla, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.